Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus

Bibliography

• Amylin Pharmaceiticals, Inc. Byettta (exenatide) package insert. San Diego, CA; 2005
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1998 to 2000 among US. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 2000;133:73-74
   PubMed Web of Science ®Google Scholar
• Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-1044
   PubMed Web of Science ®Google Scholar
• McGarry JD. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18
   PubMed Web of Science ®Google Scholar
• Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15
   PubMed Web of Science ®Google Scholar
• Unger RH, Aguilar-Parada E, Muller WA, et al. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49:837-48
   PubMed Web of Science ®Google Scholar
• Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994;37:543-51
   PubMed Web of Science ®Google Scholar
• Schwartz JG, Green GM, Guan D, et al. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996;19:468-71
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206
   PubMed Web of Science ®Google Scholar
• Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003;3:365-72
   PubMedGoogle Scholar
• Ahren B. Insulinotropic action of truncated glucagon-like peptide in mice. Acta Physiol Scand 1995;153:205-6
   PubMedGoogle Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagons-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and healthy subjects. Diabetes 1995;44:1126-31
   PubMed Web of Science ®Google Scholar
• Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, et al. Phamocokinetics, pharmacodynemics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
   PubMed Web of Science ®Google Scholar
• Calara F, Taylor K, Han J, et al. A randomized, open-label crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exedin-4). Clin Ther 2005;27:210-15
   PubMed Web of Science ®Google Scholar
• Mager DE, Abernethy DR, Egan JM, et al. Exedin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharm Exp Ther 2004;311:830-5
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
   PubMed Web of Science ®Google Scholar
• Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-52
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner R, Han J, et al. Effects of exenatide(exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• Kendal DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMedGoogle Scholar
• Blonde L, Trautmann M, Holcombe J, et al. Effects of exenatide (exendin-4) on glycemic control and weight in overweight patients with type 2 diabetes [abstract]. Obes Res 2004;12(Suppl):A39
   Google Scholar
• Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in health volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-61
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Jons D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare P, Skrivanek Z, et al. Exenatide: postprandial glucose pharmacodynamics at various dosing times relative to a meal in patients with type 2 diabetes. Diabetologia 2004;47(Suppl 1):A280
   Google Scholar
• Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Int Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Diabetes 2005;54(Suppl 1):A4-5
   Web of Science ®Google Scholar
• King AB, Wolfe G, Healy S. Clinical observations of exenatide treatment. Lett Diabetes Care 2006;29:1984
   PubMedGoogle Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. for the Duration-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes; a randomized, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Kolterman O, Young G, Parker J, et al. Stimulation of endogenous insulin secretion by subcutaneous AC-2993 (synthetic exendin-4) in healthy overnight fasted volunteers. Diabetes 1999;48(Suppl 1):A199
   Google Scholar
• Vella A, Shah P, Reed AS, et al. Lack of effect of exendin-4 and glucagons-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002;45:1410-1415
   PubMed Web of Science ®Google Scholar
• Fineman M, Shen L, Smitzi J, et al. Unique study design: evaluation of the effect of dose titration on dose-limiting nausea. Clin Pharmacol Ther 2002;71:P19
   Google Scholar
• Fineman M, Young A, Gaines E, et al. Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC-2993) in subjects with type 2 diabetes. Diabetes 2000;49(Suppl 1):A106
   Google Scholar
• Phillips L, Fineman M, Tylor K, et al. Population modeling to guide phase 3 dose selection for AC-2993 (synthetic exendin-4). Clin Pharmacol Ther 2002;71:(poster 96)
   Google Scholar
• Taylor K, Kim D, Bicsak T, et al. Continuous subcutaneous infusion of AC-2993 (synthetic exendin-4) provide sustained day-long glycemic control to patients with type 2 diabetes. Diabetes 2002;51(Suppl 2):A85
   Google Scholar
• Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403
   PubMed Web of Science ®Google Scholar
• Ahmad SR, Swann J. Food and Drug Administration. Letter to the editor: reply to Exenatide and rare adverse events. N Engl J Med 2008;358:1970-71
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis. A case report. Diabetes Care 2006;29:471
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Braun D, Kolterman O. Letter to the editor: reply to Exenatide and rare adverse events. N Engl J Med 2008;358:1971-72
   Web of Science ®Google Scholar